Tucker SP - Search Results

1

A zanamivir dimer with prophylactic and enhanced therapeutic activity against influenza viruses.

Tarbet EB, Hamilton S, Vollmer AH, Luttick A, Ng WC, Pryor M, Hurst BL, Crawford S, Smee DF, Tucker SP. Tarbet EB, et al. Among authors: tucker sp. J Antimicrob Chemother. 2014 Aug;69(8):2164-74. doi: 10.1093/jac/dku127. Epub 2014 Apr 28. J Antimicrob Chemother. 2014. PMID: 24777908 Free PMC article.

2

Methods to determine mechanism of action of anti-influenza inhibitors.

Luttick A, Hamilton S, Tucker SP. Luttick A, et al. Among authors: tucker sp. Methods Mol Biol. 2013;1030:383-406. doi: 10.1007/978-1-62703-484-5_30. Methods Mol Biol. 2013. PMID: 23821284

3

Characterization of drug-resistant influenza virus A(H1N1) and A(H3N2) variants selected in vitro with laninamivir.

Samson M, Abed Y, Desrochers FM, Hamilton S, Luttick A, Tucker SP, Pryor MJ, Boivin G. Samson M, et al. Among authors: tucker sp. Antimicrob Agents Chemother. 2014 Sep;58(9):5220-8. doi: 10.1128/AAC.03313-14. Epub 2014 Jun 23. Antimicrob Agents Chemother. 2014. PMID: 24957832 Free PMC article.

4

Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase.

Watson KG, Cameron R, Fenton RJ, Gower D, Hamilton S, Jin B, Krippner GY, Luttick A, McConnell D, MacDonald SJ, Mason AM, Nguyen V, Tucker SP, Wu WY. Watson KG, et al. Among authors: tucker sp. Bioorg Med Chem Lett. 2004 Mar 22;14(6):1589-92. doi: 10.1016/j.bmcl.2003.09.102. Bioorg Med Chem Lett. 2004. PMID: 15006410

5

In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity.

Barnard DL, Hubbard VD, Smee DF, Sidwell RW, Watson KG, Tucker SP, Reece PA. Barnard DL, et al. Among authors: tucker sp. Antimicrob Agents Chemother. 2004 May;48(5):1766-72. doi: 10.1128/AAC.48.5.1766-1772.2004. Antimicrob Agents Chemother. 2004. PMID: 15105133 Free PMC article.

6

Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a once-weekly dosing regimen.

Macdonald SJ, Watson KG, Cameron R, Chalmers DK, Demaine DA, Fenton RJ, Gower D, Hamblin JN, Hamilton S, Hart GJ, Inglis GG, Jin B, Jones HT, McConnell DB, Mason AM, Nguyen V, Owens IJ, Parry N, Reece PA, Shanahan SE, Smith D, Wu WY, Tucker SP. Macdonald SJ, et al. Among authors: tucker sp. Antimicrob Agents Chemother. 2004 Dec;48(12):4542-9. doi: 10.1128/AAC.48.12.4542-4549.2004. Antimicrob Agents Chemother. 2004. PMID: 15561823 Free PMC article.

7

An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against Human Rhinovirus.

Feil SC, Hamilton S, Krippner GY, Lin B, Luttick A, McConnell DB, Nearn R, Parker MW, Ryan J, Stanislawski PC, Tucker SP, Watson KG, Morton CJ. Feil SC, et al. Among authors: tucker sp. ACS Med Chem Lett. 2012 Feb 13;3(4):303-7. doi: 10.1021/ml2002955. eCollection 2012 Apr 12. ACS Med Chem Lett. 2012. PMID: 24900468 Free PMC article.

8

2-Ethoxybenzoxazole as a bioisosteric replacement of an ethyl benzoate group in a human rhinovirus (HRV) capsid binder.

Brown RN, Cameron R, Chalmers DK, Hamilton S, Luttick A, Krippner GY, McConnell DB, Nearn R, Stanislawski PC, Tucker SP, Watson KG. Brown RN, et al. Among authors: tucker sp. Bioorg Med Chem Lett. 2005 Apr 15;15(8):2051-5. doi: 10.1016/j.bmcl.2005.02.054. Bioorg Med Chem Lett. 2005. PMID: 15808466

9

Derivatives of imidazotriazine and pyrrolotriazine C-nucleosides as potential new anti-HCV agents.

Draffan AG, Frey B, Fraser BH, Pool B, Gannon C, Tyndall EM, Cianci J, Harding M, Lilly M, Hufton R, Halim R, Jahangiri S, Bond S, Jeynes TP, Nguyen VT, Wirth V, Luttick A, Tilmanis D, Pryor M, Porter K, Morton CJ, Lin B, Duan J, Bethell RC, Kukolj G, Simoneau B, Tucker SP. Draffan AG, et al. Among authors: tucker sp. Bioorg Med Chem Lett. 2014 Nov 1;24(21):4984-8. doi: 10.1016/j.bmcl.2014.09.030. Epub 2014 Sep 21. Bioorg Med Chem Lett. 2014. PMID: 25288185

10

1,2,3,9b-Tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones as a new class of respiratory syncytial virus (RSV) fusion inhibitors. Part 2: identification of BTA9881 as a preclinical candidate.

Bond S, Draffan AG, Fenner JE, Lambert J, Lim CY, Lin B, Luttick A, Mitchell JP, Morton CJ, Nearn RH, Sanford V, Anderson KH, Mayes PA, Tucker SP. Bond S, et al. Among authors: tucker sp. Bioorg Med Chem Lett. 2015 Feb 15;25(4):976-81. doi: 10.1016/j.bmcl.2014.11.024. Epub 2014 Nov 14. Bioorg Med Chem Lett. 2015. PMID: 25595685

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

59 results

Search Page

Filters